These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21083252)

  • 21. Development of anti-cancer drugs.
    Arrondeau J; Gan HK; Razak AR; Paoletti X; Le Tourneau C
    Discov Med; 2010 Oct; 10(53):355-62. PubMed ID: 21034677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.
    Ings RM
    Bioanalysis; 2009 Oct; 1(7):1293-305. PubMed ID: 21083052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of microdosing clinical study -- why necessary and how useful?
    Sugiyama Y; Yamashita S
    Adv Drug Deliv Rev; 2011 Jun; 63(7):494-502. PubMed ID: 20950660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug development: assessment of pharmacogenetic studies by Spanish research ethics committees.
    Dal-Ré R; Luque I; Torres R; Lahuerta J
    Pharmacogenomics J; 2009 Apr; 9(2):86-9. PubMed ID: 19079365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The odyssey of marine pharmaceuticals: a current pipeline perspective.
    Mayer AM; Glaser KB; Cuevas C; Jacobs RS; Kem W; Little RD; McIntosh JM; Newman DJ; Potts BC; Shuster DE
    Trends Pharmacol Sci; 2010 Jun; 31(6):255-65. PubMed ID: 20363514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational strategies for development of monoclonal antibodies from discovery to the clinic.
    Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L
    Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human microdosing for the prediction of patient response.
    Henderson PT; Pan CX
    Bioanalysis; 2010 Mar; 2(3):373-6. PubMed ID: 21083245
    [No Abstract]   [Full Text] [Related]  

  • 29. [The discovery process in the pharmaceutical industry].
    Scatton B
    J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Better protection for human subjects is outcome of very early clinical trials.
    Maloney DM
    Hum Res Rep; 2006 May; 21(5):1-2. PubMed ID: 16832915
    [No Abstract]   [Full Text] [Related]  

  • 31. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens.
    Caldwell GW
    Curr Opin Drug Discov Devel; 2000 Jan; 3(1):30-41. PubMed ID: 19649835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic discovery in the twenty-first century: current trends and future perspectives.
    Donadio S; Maffioli S; Monciardini P; Sosio M; Jabes D
    J Antibiot (Tokyo); 2010 Aug; 63(8):423-30. PubMed ID: 20551985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antihypertensive drug development: current challenges and future opportunities.
    Feig PU; Roy S; Cody RJ
    J Am Soc Hypertens; 2010; 4(4):163-73. PubMed ID: 20537610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of NEDO project on microdosing clinical studies: toward the eIND study in Japan.
    Yamashita S
    Drug Metab Pharmacokinet; 2011; 26(6):549-50. PubMed ID: 22214558
    [No Abstract]   [Full Text] [Related]  

  • 37. Experiences with learning and confirming in drug and biological development.
    Patterson SD
    Clin Pharmacol Ther; 2010 Aug; 88(2):161-3. PubMed ID: 20648033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond profiling: using ADMET models to guide decisions.
    Segall M; Champness E; Obrezanova O; Leeding C
    Chem Biodivers; 2009 Nov; 6(11):2144-51. PubMed ID: 19937845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New approaches in preclinical and clinical pharmacokinetics.
    Graham MA; Kaye SB
    Cancer Surv; 1993; 17():27-49. PubMed ID: 8137345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expanding utility of microdosing.
    Lappin G
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):401-6. PubMed ID: 27137711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.